Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director · President and CEO | February 10, 2026 | February 12, 2026 |
| VIVEVE MEDICAL, INC.VIVE · Entity 11899 | Director | January 03, 2023 | January 05, 2023 |
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | Director | December 12, 2025 | December 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phathom Pharmaceuticals, Inc.
Report date February 10, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 379,592 |
Reported balance
After 2026-02-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-10 · Grant · Acquired 12,362 · Balance 379,592 F1: Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026. F2: Includes 2,410 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026. |
| Common StockSEC Table I · non-derivative | Direct | 373,315 |
Reported balance
After 2026-02-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-10 · Tax withholding · Disposed 6,277 · Balance 373,315 F3: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026.
F2: Includes 2,410 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026.
F3: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
VIVEVE MEDICAL, INC.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 72,000 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 72,000 · Balance 72,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock.
F2: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer.
Yarrow Bioscience, Inc.
Report date December 12, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2035-12-11 | Direct | 20,000 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KalVista Pharmaceuticals, Inc.
Report date November 21, 2016 · Filed November 22, 2016
Section 16 reporting ended · disclosed 2016-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2016-11-21 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2016-11-21 · Exercise / conversion · Acquired 1,125 · Balance 1,125 F1: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. Row 2 · 2016-11-21 · Tax withholding · Disposed 1,026 · Balance 99 F1: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. Row 3 · 2016-11-21 · Other · Disposed 99 · Balance 0 F1: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2023-06-06 | Direct | 0 |
Reported balance
After 2016-11-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-21 · Exercise / conversion · Acquired 1,125 · Balance 0 F1: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. F2: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction.
F2: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2016 Filed Nov 22, 2016 16:14 UTC | KalVista Pharmaceuticals, Inc. CBYL · Entity 39180 | OtherCommon Stock | 99 | $8.59 | $850.73 |
DisclosureSEC source: 0001140361-16-087582 · doc1.xml · nonDerivative · entry 3 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 16:14 UTC | KalVista Pharmaceuticals, Inc. CBYL · Entity 39180 | Tax withholdingCommon Stock | 1,026 | $8.59 | $8,816.62 |
DisclosureSEC source: 0001140361-16-087582 · doc1.xml · nonDerivative · entry 2 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99 F1 · kind: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 16:14 UTC | KalVista Pharmaceuticals, Inc. CBYL · Entity 39180 | Exercise / conversionCommon Stock | 1,125 | $7.84 | $8,820.00 |
DisclosureSEC source: 0001140361-16-087582 · doc1.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.